Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

PURPOSE: Angiogenesis is important for epithelial ovarian cancer (EOC) growth, and blocking angiogenesis can lead to EOC regression. Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, and c-kit. PATIENTS AND METHODS: We c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Matulonis, Ursula A., Berlin, Suzanne, Ivy, Percy, Tyburski, Karin, Krasner, Carolyn, Zarwan, Corrine, Berkenblit, Anna, Campos, Susana, Horowitz, Neil, Cannistra, Stephen A., Lee, Hang, Lee, Julie, Roche, Maria, Hill, Margaret, Whalen, Christin, Sullivan, Laura, Tran, Chau, Humphreys, Benjamin D., Penson, Richard T.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2009
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2792954/
https://ncbi.nlm.nih.gov/pubmed/19826113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.2777
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller